Get the app
public
ios_share
OncoPharm
chevron_right
Repotrectinib & Capivasertib
Nov 23, 2023
23:49
forum
Ask episode
play_arrow
Play
view_agenda
Chapters
auto_awesome
Transcript
info_circle
Episode notes
FDA has approved two new kinase inhibitors: one for ROS1 (+) NSCLC and one for PIK3CA/AKT/PTEN altered breast cancer.
